| Identification | Back Directory | [Name]
Imipenem-Cilastatin sodium hydrate | [CAS]
92309-29-0 | [Synonyms]
Thienam
Primaxin
Tienam 500
Mk 787-mk 791 mixture
Mk 0787-mk 0791 mixture
85960-17-4 (Hydrochloride salt)
Imipenem-Cilastatin sodium hydrate
Imipenem-Cilastatin sodium hydrate USP/EP/BP
IMipeneM and Cilastatin SodiuM with SodiuM Bicarbonate
7-[(2S)-2-amino-2-carboxy-ethyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopro panecarbonyl]amino]hept-2-enoic acid: (5R)-3-[2-(aminomethylideneamino )ethylsulfanyl]-6-(1-hydroxyethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene -2-carboxylic acid
1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-((1R)-1-hydroxyethyl)-3-((2-((iminomethyl)amino)ethyl)thio)-7-oxo-, (5R,6S)-, mixt. with (2Z)-7-(((2R)-2-amino-2-carboxyethyl)thio)-2-((((1S)-2,2-dimethylcyclopropyl)carbonyl)amino)-2-heptenoic acid
Sodium (Z)-7-[(2R)-2-amino-3-hydroxy-3-oxopropyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoate (5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-(1-hydroxyethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid hydrate
1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-3-((2-((iminomethyl)amino)ethyl)thio)-7-oxo-, (5R-(5alpha,6alpha(R*)))-, mixt. with (R-(R*,S*-(Z)))-7-((2-amino-2-carboxyethyl)thio)-2-(((2,2-dimethylcyclopropyl)carbonyl)amino)-2-heptanoic acid | [EINECS(EC#)]
1592732-453-0 | [Molecular Formula]
C28H43N5O9S2 | [MOL File]
92309-29-0.mol | [Molecular Weight]
697.8 |
| Hazard Information | Back Directory | [Clinical Use]
Antibacterial agent | [Drug interactions]
Potentially hazardous interactions with other drugs
Antiepileptics: reduced valproate concentration -
avoid.
Antivirals: convulsions reported with concomitant
administration of ganciclovir and valganciclovir.
Ciclosporin: variable reports of increase / no change
in ciclosporin levels, and of neurotoxicity. | [Metabolism]
When administered alone, imipenem is metabolised in
the kidneys by dehydropeptidase-I, an enzyme in the
brush border of the renal tubules, to inactive, nephrotoxic
metabolites, with only about 5 to 40 or 45% of a dose
excreted in the urine as unchanged active drug.
Cilastin inhibits the metabolism of imipenem. When
given with cilastatin about 70% of an intravenous dose of
imipenem is recovered unchanged in the urine within 10
hours. Cilastatin is also excreted mainly in the urine, the
majority as unchanged drug and about 12% as N-acetyl
cilastatin. Less than 1% of imipenem is excreted via the
bile in the faeces. |
|
|